BOXED O
WARNING O
: O
WARNING O
: O
ESAs O
INCREASE O
THE O
RISK O
OF O
DEATH O
, O
MYOCARDIAL B-OSE_Labeled_AE
INFARCTION I-OSE_Labeled_AE
, O
STROKE O
, O
VENOUS B-OSE_Labeled_AE
THROMBOEMBOLISM I-OSE_Labeled_AE
, O
THROMBOSIS B-OSE_Labeled_AE
OF I-OSE_Labeled_AE
VASCULAR I-OSE_Labeled_AE
ACCESS I-OSE_Labeled_AE
ANDTUMOR O
PROGRESSION O
OR O
RECURRENCE O
WARNING O
: O
ESAs O
INCREASE O
THE O
RISK O
OF O
DEATH O
, O
MYOCARDIAL O
INFARCTION O
, O
STROKE O
, O
VENOUS O
THROMBOEMBOLISM O
, O
THROMBOSIS O
OF O
VASCULAR O
ACCESS O
AND O
TUMOR O
PROGRESSION O
OR O
RECURRENCE O
Chronic B-Not_AE_Candidate
Kidney I-Not_AE_Candidate
Disease I-Not_AE_Candidate
: O
* O
In O
controlled O
trials O
, O
patients O
experienced O
greater O
risks O
for O
death B-NonOSE_AE
, O
serious O
adverse B-OSE_Labeled_AE
cardiovascular I-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
, O
and O
stroke B-OSE_Labeled_AE
when O
administered O
erythropoiesis-stimulating O
agents O
( O
ESAs O
) O
to O
target O
a O
hemoglobin O
level O
of O
greater O
than O
11 O
g/dL O
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
. O

* O
No O
trial O
has O
identified O
a O
hemoglobin O
target O
level O
, O
Aranesp O
dose O
, O
or O
dosing O
strategy O
that O
does O
not O
increase O
these O
risks O
[ O
see O
Dosage O
and O
Administration O
( O
2.2 O
) O
] O
. O

* O
Use O
the O
lowest O
Aranesp O
dose O
sufficient O
to O
reduce O
the O
need O
for O
red O
blood O
cell O
( O
RBC O
) O
transfusions O
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
. O

Cancer B-Not_AE_Candidate
: O
* O
ESAs O
shortened O
overall O
survival O
and/or O
increased O
the O
risk O
of O
tumor B-OSE_Labeled_AE
progression I-OSE_Labeled_AE
or O
recurrence O
in O
clinical O
studies O
of O
patients O
with O
breast B-Not_AE_Candidate
, O
non-small O
cell O
lung O
, O
head O
and O
neck O
, O
lymphoid O
, O
and O
cervical O
cancers I-Not_AE_Candidate
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
. O

* O
To O
decrease O
these O
risks O
, O
as O
well O
as O
the O
risk O
of O
serious O
cardiovascular B-NonOSE_AE
and O
thromboembolic O
reactions I-NonOSE_AE
, O
use O
the O
lowest O
dose O
needed O
to O
avoid O
RBC O
transfusions O
[ O
see O
Dosage O
and O
Administration O
( O
2.3 O
) O
] O
. O

* O
Use O
ESAs O
only O
for O
anemia B-Not_AE_Candidate
from I-Not_AE_Candidate
myelosuppressive I-Not_AE_Candidate
chemotherapy I-Not_AE_Candidate
[ O
see O
Indications O
and O
Usage O
( O
1.2 O
) O
] O
. O

* O
ESAs O
are O
not O
indicated O
for O
patients O
receiving O
myelosuppressive B-Not_AE_Candidate
chemotherapy I-Not_AE_Candidate
when O
the O
anticipated O
outcome O
is O
cure O
[ O
see O
Indications O
and O
Usage O
( O
1.3 O
) O
] O
. O

* O
Discontinue O
following O
the O
completion O
of O
a O
chemotherapy O
course O
[ O
see O
Dosage O
and O
Administration O
( O
2.3 O
) O
] O
. O

EXCERPT O
: O
WARNING O
: O
ESAs O
INCREASE O
THE O
RISK O
OF O
DEATH O
, O
MYOCARDIAL O
INFARCTION O
, O
STROKE O
, O
VENOUS O
THROMBOEMBOLISM O
, O
THROMBOSIS O
OF O
VASCULAR O
ACCESS O
AND O
TUMOR O
PROGRESSION O
OR O
RECURRENCE O
See O
full O
prescribing O
information O
for O
complete O
boxed O
warning O
. O

Chronic O
Kidney O
Disease O
: O
* O
In O
controlled O
trials O
, O
patients O
experienced O
greater O
risks O
for O
death O
, O
serious O
adverse O
cardiovascular O
reactions O
, O
and O
stroke O
when O
administered O
erythropoiesis-stimulating O
agents O
( O
ESAs O
) O
to O
target O
a O
hemoglobin O
level O
of O
greater O
than O
11 O
g/dL O
( O
5.1 O
) O
. O

* O
No O
trial O
has O
identified O
a O
hemoglobin O
target O
level O
, O
Aranesp O
dose O
, O
or O
dosing O
strategy O
that O
does O
not O
increase O
these O
risks O
( O
2.2 O
) O
. O

* O
Use O
the O
lowest O
Aranesp O
dose O
sufficient O
to O
reduce O
the O
need O
for O
red O
blood O
cell O
( O
RBC O
) O
transfusions O
( O
5.1 O
) O
. O

Cancer O
: O
* O
ESAs O
shortened O
overall O
survival O
and/or O
increased O
the O
risk O
of O
tumor O
progression O
or O
recurrence O
in O
clinical O
studies O
of O
patients O
with O
breast O
, O
non-small O
cell O
lung O
, O
head O
and O
neck O
, O
lymphoid O
, O
and O
cervical O
cancers O
( O
5.2 O
) O
. O

* O
Use O
the O
lowest O
dose O
to O
avoid O
RBC O
transfusions O
( O
2.3 O
) O
. O

* O
Use O
ESAs O
only O
for O
anemia O
from O
myelosuppressive O
chemotherapy O
( O
1.2 O
) O
. O

* O
ESAs O
are O
not O
indicated O
for O
patients O
receiving O
myelosuppressive O
chemotherapy O
when O
the O
anticipated O
outcome O
is O
cure O
( O
1.3 O
) O
. O

* O
Discontinue O
following O
the O
completion O
of O
a O
chemotherapy O
course O
( O
2.3 O
) O
. O

